What decision does “What Counts as Evidence for Drug Target Validation?” help make?

It supports a bounded decision about which evidence classes materially strengthen or weaken a target thesis. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.

Can computation validate the final scientific claim?

No. No single database score or model output fully validates a therapeutic target. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.

When should the project stop or reframe?

Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.

Drug Discovery

What Counts as Evidence for Drug Target Validation?

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

What Counts as Evidence for Drug Target Validation? can shorten the search only by eliminating weak directions early. Start with which evidence classes materially strengthen or weaken a target thesis; compare mechanisms against causal human evidence, perturbation, pharmacology, orthogonal assays, replication, context, and safety; and try to break the ranking with this challenge: test whether orthogonal interventions produce the predicted disease-relevant change. A negative result is valuable when it prevents the wrong validation cycle.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which evidence classes materially strengthen or weaken a target thesis

Why the problem is difficult

The article-specific identification challenge is whether the question “which evidence classes materially strengthen or weaken a target thesis” can be resolved using causal human evidence, perturbation, pharmacology, orthogonal assays, replication, context, and safety, rather than merely restated in new language.

A falsifier-first workflow

Define the decision precisely: which evidence classes materially strengthen or weaken a target thesis.
Build a source and data ledger around causal human evidence, perturbation, pharmacology, orthogonal assays, replication, context, and safety.
Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
Run the lowest-cost discriminating challenge: test whether orthogonal interventions produce the predicted disease-relevant change.
Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

Decision impact: would the result materially change the choice about which evidence classes materially strengthen or weaken a target thesis?
Evidence fit: does the available evidence—causal human evidence, perturbation, pharmacology, orthogonal assays, replication, context, and safety—directly address the decision rather than merely correlate with it?
Discrimination: does the preferred route predict an outcome a credible alternative does not?
Robustness: does the ranking survive the challenge “test whether orthogonal interventions produce the predicted disease-relevant change”?
Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

causal human evidence, perturbation, pharmacology, orthogonal assays, replication, context, and safety

Counterevidence

For this decision, a result from “test whether orthogonal interventions produce the predicted disease-relevant change” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which evidence classes materially strengthen or weaken a target thesis or exposes why the available evidence cannot resolve it.

Fastest falsifier

test whether orthogonal interventions produce the predicted disease-relevant change

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “test whether orthogonal interventions produce the predicted disease-relevant change” without an independently supported alternative mechanism.

Evidence ceiling

No single database score or model output fully validates a therapeutic target.

Sources and starting points

Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
ChEMBL — Curated bioactivity information for compounds, assays, and targets.
ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
PubChem — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
FDA Drug Development and Approval Process — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “What Counts as Evidence for Drug Target Validation?” help make?: It supports a bounded decision about which evidence classes materially strengthen or weaken a target thesis. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?: test whether orthogonal interventions produce the predicted disease-relevant change
Can computation validate the final scientific claim?: No. No single database score or model output fully validates a therapeutic target. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?: Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.